 |
| Anti-Obesity Drug Market |
Anti-obesity drugs help promote weight loss by reducing appetite or absorption of fat and calories. These drugs provide an effective solution for weight management and reduction of several health risks associated with obesity such as diabetes, cardiovascular diseases, and certain cancers. The global Anti-Obesity Drug Market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing Obesity Rates Drive Demand for Anti-Obesity Drugs
One of the key trends driving the growth of the anti-obesity drug market is the
increasing prevalence of obesity worldwide. Obesity significantly raises the
risk of various chronic diseases and disorders. According to the WHO, globally
over 1.9 billion adults were overweight in 2016, of which over 650 million were
obese. In addition, nearly 340 million children and adolescents aged 5-19 were
overweight or obese in 2016. This rising obesity rates has increased demand for
effective weight management treatments, thereby supporting the demand for
anti-obesity drugs during the forecast period.
Segment Analysis
The global anti-obesity drug market is dominated by the appetite suppressants
sub-segment. These drugs work by increasing the level of hormones that create a
feeling of fullness in the body, thereby reducing appetite and resulting in
weight loss. Their effectiveness in curbing appetite make them the preferred
choice for weight management.
Key Takeaways
The global Anti-Obesity
Drug Market Growth is expected to witness high growth over the forecast
period of 2023 to 2030.
Regional analysis: North America currently holds the largest share of the
global anti-obesity drug market and is expected to maintain its dominance
through 2030. high obesity rates, rising awareness regarding weight management,
and easy availability of drugs drive the growth of the market in the region.
Asia Pacific is anticipated to witness the fastest growth propelled by growing
health consciousness, increasing disposable income leading to better access to
healthcare, and rising prevalence of obesity in countries like China and India.
Key players operating in the anti-obesity drug market are ARJO, Etac AB,
Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation,
Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation,
Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria
Corporation (Handicare Group AB), among others.
0 Comments